Can a simple inhaler stop lung bleeding?
NCT ID NCT04961528
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether inhaling tranexamic acid or terlipressin can quickly stop mild to severe coughing up blood (hemoptysis) without needing invasive procedures. 315 adults were randomly assigned to receive one of the two drugs or a placebo via nebulizer for 3 days. The goal was to see if these drugs could control bleeding within the first 3 days of hospitalization.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- inhaled tranexamic acid or terlipressin
- What this could lead to
- If it works, this could offer a simple, drug-based way to quickly stop coughing up blood without needing invasive procedures.
- What could go wrong
- This is a completed phase 3 trial, but results are not yet published. The drugs may not work better than placebo, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
315 people
The number who actually took part.
- Started
-
Mar 2022
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients over 18 years, under 90 years * Mild to severe hemoptysis that has been going on for less than 7 days * Total expectorate blood ranging from 50 ml to 200 ml * Admission in emergency department or ICU for less than 12 hours * Social security affiliation * Signed informed consent * For child-bearing aged women, efficient contraception includes oral oestrogen- progestin, oral progestin, progestin implants and all types of intrauterine devices Exclusion Criteria: * Need for mechanical ventilation * Cystic fibrosis * Pregnancy or breast feeding * Contraindication for contrast agents injection (renal failure with creatinin clearance \< 30mL/min, know allergy to contrast agents injection) * Known hypersensitivity to TXA or TER or one of its excipients * Know previous cardiac arrhythmia (atrial fibrillation, atrial flutter..) * Contraindication to TXA (including renal failure with creatinin clearance \< 30mL/min) or TER therapy : * acute myocardial infarction in the 6 past months, * intrathecal injection in the 3 past months, * seizure in the past 3 months * Participation in another interventional study or being in the exclusion period at the end of a previous study. * Patient under tutorship or / guardianship, and incapable to give informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hemoptysis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP, Hôpital Européen Georges Pompidou
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.